Aceso Life Science Group Limited provided unaudited consolidated earnings guidance for the year ended 31 March 2022. For the period, the Group is expected to record a net loss of the Group at approximately HKD 572 million, as compared to the net loss of the Group of approximately HKD 348 million for the year ended 31 March 2021. The primary reasons for significant decline in the Group's financial performance were (i)loss on financial assets through profit or loss for the year ended 31 March 2022, where there is a substantial loss from its investments in fund with investments in private equity and listed securities in companies located in the Greater China Region; and (ii) loss in sharing of result of associates and joint ventures.